A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This 2 arm study will compare the effects of aleglitazar and Actos, added to preexisting oral
antihyperglycemic therapy and/or diet and exercise, on renal function in patients with type 2
diabetes, and normal or mildly impaired renal function. Eligible patients will be randomized
to receive either aleglitazar 0.6mg p.o. or Actos 45mg p.o. daily. Renal function and
efficacy parameters will be assessed at intervals during the treatment period. The
anticipated time on study treatment is 3-12 months, and the target sample size is 100-500
individuals.